Skip to main content
https://pbs.twimg.com/media/FvDEWrFWwAAY8gp.jpg
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV
Dr. John Cush
01-05-2023
×